Kashmox 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg and Clavulanic Acid 125 mg, designed to treat a broad spectrum of bacterial infections. Amoxycillin, a beta-lactam antibiotic, exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Amoxycillin by preventing degradation by beta-lactamase enzymes produced by resistant bacteria. This synergistic combination is effective against various Gram-positive and Gram-negative pathogens, including strains resistant to Amoxycillin alone. Kashmox 625 is indicated for the treatment of respiratory tract infections such as sinusitis, bronchitis, and pneumonia; urinary tract infections; skin and soft tissue infections; and infections of the ear, nose, and throat. The medication should be used as prescribed by a healthcare professional, with dosage and duration tailored to the severity and type of infection. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypersensitivity reactions, though rare, require immediate medical attention. Caution is advised in patients with a history of penicillin allergy or hepatic impairment. Kashmox 625 Tablet offers an effective therapeutic option in managing bacterial infections resistant to standard beta-lactam antibiotics.

Dosage & How to Use